New pill aims to stop Narcolepsy's sudden muscle weakness

NCT ID NCT05059223

Completed Symptom relief Sponsor: Axsome Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental drug called AXS-12 (reboxetine) in 90 people with narcolepsy who experience cataplexy (sudden muscle weakness) and excessive daytime sleepiness. Participants took either the drug or a placebo twice daily for several weeks. The main goal was to see if AXS-12 could reduce the number of cataplexy attacks per week.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AXS-12 (reboxetine)
What this could lead to: If it works, this could provide a new treatment option to reduce sudden muscle weakness and improve daytime alertness in people with narcolepsy.
What could go wrong: This is a Phase 3 trial, but results are not yet published. The drug may not prove more effective than placebo, and side effects like insomnia or increased blood pressure are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cataplexy Disorders of Excessive Somnolence hypersomnia narcolepsy narcolepsy 1 narcolepsy-cataplexy syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CATAPLEXY EXCESSIVE DAYTIME SLEEPINESS NARCOLEPSY

Contacts and locations

Locations

Clinical Research Site

Alabaster, Alabama, 35007, United States
Clinical Research Site

Peoria, Arizona, 85381, United States
Clinical Research Site

Phoenix, Arizona, 85054, United States
Clinical Research Site

Redwood City, California, 94063, United States
Clinical Research Site

San Diego, California, 92103, United States
Clinical Research Site

Santa Ana, California, 92705, United States
Clinical Research Site

Santa Monica, California, 90404, United States
Clinical Research Site

Boulder, Colorado, 80301, United States
Clinical Research Site

Colorado Springs, Colorado, 80918, United States
Clinical Research Site

Brandon, Florida, 33511, United States
Clinical Research Site

Clearwater, Florida, 33765, United States
Clinical Research Site

Doral, Florida, 33122, United States
Clinical Research Site

Kissimmee, Florida, 34741, United States
Clinical Research Site

Miami, Florida, 33176, United States
Clinical Research Site

Miami Lakes, Florida, 33016, United States
Clinical Research Site

St. Petersburg, Florida, 33707, United States
Clinical Research Site

Tampa, Florida, 33634, United States
Clinical Research Site

Winter Park, Florida, 32789, United States
Clinical Research Site

Atlanta, Georgia, 30315, United States
Clinical Research Site

Atlanta, Georgia, 30328, United States
Clinical Research Site

Gainesville, Georgia, 30501, United States
Clinical Research Site

Macon, Georgia, 31210, United States
Clinical Research Site

Stockbridge, Georgia, 30281, United States
Clinical Research Site

Honolulu, Hawaii, 96817, United States
Clinical Research Site

Peoria, Illinois, 61637, United States
Clinical Research Site

Fort Wayne, Indiana, 46804, United States
Clinical Research Site

Chevy Chase, Maryland, 20815, United States
Clinical Research Site

Newton, Massachusetts, 02459, United States
Clinical Research Site

North Dartmouth, Massachusetts, 02747, United States
Clinical Research Site

Kalamazoo, Michigan, 49008, United States
Clinical Research Site

Novi, Michigan, 48377, United States
Clinical Research Site

St Louis, Missouri, 63123, United States
Clinical Research Site

Las Vegas, Nevada, 89106, United States
Clinical Research Site

Neptune City, New Jersey, 07753, United States
Clinical Research Site

Brooklyn, New York, 11230, United States
Clinical Research Site

New Hyde Park, New York, 11040, United States
Clinical Research Site

Denver, North Carolina, 28037, United States
Clinical Research Site

Gastonia, North Carolina, 28054, United States
Clinical Research Site

Huntersville, North Carolina, 28078, United States
Clinical Research Site

Cincinnati, Ohio, 45245, United States
Clinical Research Site

Wyomissing, Pennsylvania, 19610, United States
Clinical Research Site

Charleston, South Carolina, 29425, United States
Clinical Research Site

Columbia, South Carolina, 29201, United States
Clinical Research Site

Austin, Texas, 78731, United States
Clinical Research Site

San Antonio, Texas, 78229, United States
Clinical Research Site

Sugar Land, Texas, 77478, United States
Clinical Research Site

Williamsburg, Virginia, 23188, United States
Clinical Research Site

Markham, Ontario, L3R 1A3, Canada
Clinical Research Site

Toronto, Ontario, M4P 1P2, Canada
Clinical Research Site

Toronto, Ontario, M5S 3A3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.